Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials

Rationale & Objective: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This analysis explored the efficacy and safety of finerenone in Black patients. Study Design: Subanalysis of randomized controlled trials. Set...

Full description

Bibliographic Details
Main Authors:	John M. Flack, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luis M. Ruilope, Peter Rossing, Sharon G. Adler, Linda Fried, Kenneth Jamerson, Robert Toto, Meike Brinker, Alfredo E. Farjat, Peter Kolkhof, Robert Lawatscheck, Amer Joseph, George L. Bakris
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	Kidney Medicine
Subjects:	Cardiorenal chronic kidney disease clinical trial finerenone race type 2 diabetes
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590059523001486

Similar Items

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
by: Nicholas Chiu, et al.
Published: (2022-04-01)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
by: Peter Kolkhof, et al.
Published: (2022-08-01)

Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China
by: Haitao Zhang, et al.
Published: (2023-08-01)

POS-829 Incidence and predictors of hyperkalaemia in patients with CKD and T2D in the FIDELIO-DKD trial
by: R. Agarwal, et al.
Published: (2021-04-01)

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
by: Sylvia E. Rosas, et al.
Published: (2023-10-01)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
by: Monarch Shah, et al.
Published: (2023-09-01)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
by: Ruolin Lv, et al.
Published: (2023-02-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
by: Raquel González-Blázquez, et al.
Published: (2018-10-01)

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
by: Jack R. Jerome, et al.
Published: (2023-01-01)

Potassium management with finerenone: Practical aspects
by: Christoph Wanner, et al.
Published: (2022-11-01)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
by: Shaikh A, et al.
Published: (2022-07-01)

Co-differential genes between DKD and aging: implications for a diagnostic model of DKD
by: Hongxuan Du, et al.
Published: (2024-02-01)

Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
by: Sabrina Scilletta, et al.
Published: (2023-04-01)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
by: Ixchel Lima-Posada, et al.
Published: (2023-01-01)

Sex-dependent effects of finerenone on hemostasis in normoglycemic and streptozotocin-induced diabetic mice
by: Bielicka Natalia, et al.
Published: (2023-12-01)

Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023-01-01)

FINERENONE IN CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY ANALYSIS OF LEFT VENTRICULAR HYPERTROPHY
by: Luis Matavelli, et al.
Published: (2023-09-01)

Cardiorenal benefits of finerenone: protecting kidney and heart
by: José R. González-Juanatey, et al.
Published: (2023-12-01)

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
by: Tao Jin, et al.
Published: (2023-04-01)

Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials
by: George L Bakris, et al.
Published: (2024-03-01)

Detection of DKD stage 1 and treatment are essential
by: Narisa Futrakul, et al.
Published: (2018-10-01)

Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors
by: M. Sanz-Gómez, et al.
Published: (2023-12-01)

Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease
by: Yaning Zheng, et al.
Published: (2022-01-01)

The role of lncRNAs in regulation of DKD and diabetes-related cancer
by: Yawei Cheng, et al.
Published: (2022-10-01)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
by: Dimitrios Patoulias, et al.
Published: (2022-02-01)

The Role of Immune Cells in DKD: Mechanisms and Targeted Therapies
by: Peng QY, et al.
Published: (2024-04-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
by: Dong-Lim Kim, et al.
Published: (2023-02-01)

Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies
by: Franz Schaefer, et al.
Published: (2024-03-01)

Therapeutic Advances in Diabetic Kidney Disease
by: Panagiotis I. Georgianos, et al.
Published: (2023-02-01)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01)

Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
by: Deep Dutta, et al.
Published: (2022-01-01)

Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Ming-Zhu Zhang, et al.
Published: (2022-02-01)

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials
by: Yue Du, et al.
Published: (2024-01-01)

Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study
by: David Vizcaya, et al.
Published: (2023-06-01)

Both sexes develop DKD in the CD1 uninephrectomized streptozotocin mouse model
by: Jackie Trink, et al.
Published: (2023-10-01)

Lessons learned from two randomized controlled trials: CITIES and STOP-DKD
by: Leah L. Zullig, et al.
Published: (2020-09-01)

Left-sided massive hydrothorax in a DKD patient on CAPD using icodextrin
by: Maithrayie Kumaresan, et al.
Published: (2021-01-01)

The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD
by: João Roberto de Sá, et al.
Published: (2022-06-01)